Core Concept The central idea is "Target-based Drug Discovery." Instead of screening compounds on whole cells or organisms (phenotypic screening), you start with a specific protein (e.g., a kinase, receptor, ion channel) implicated in a disease. Services then help you understand that target and find molecules that modulate it. Categories of Protein Target Services These services typically follow the drug discovery pipeline: 1. Target Identification & Validation Bioinformatics & Omics Analysis: Mining genomic, proteomic, and clinical data to identify novel disease-associated targets. Genetic Validation: CRISPR/Cas9 gene editing (knock-out/knock-in), siRNA/shRNA knockdown to confirm the target's role in disease pathways. Functional Validation: Cell-based assays to see if modulating the target affects disease-relevant phenotypes. 2. Protein Expression & Purification Recombinant Protein Production: Cloning, expressing (in E. coli, insect, or mammalian cells), and purifying milligram to gram quantities of the target protein. This is essential for structural studies and biochemical assays. Membrane Protein Expertise: Specialized services for difficult-to-express targets like GPCRs and ion channels. Tagging & Labeling: Adding tags (His, GST, FLAG) for purification or fluorescent/isotopic labels for assays. 3. Structural Biology & Biophysics X-ray Crystallography: Determining high-resolution 3D structures of protein-ligand complexes. Cryo-Electron Microscopy (Cryo-EM): For large complexes or membrane proteins unsuitable for crystallography. Nuclear Magnetic Resonance (NMR) Spectroscopy: For studying dynamics and ligand binding in solution. Surface…
CELL-SELEX (Cell-Based Systematic Evolution of Ligands by EXponential enrichment) is a selection strategy used to discover nucleic-acid aptamers—short single-stranded DNA or RNA molecules that fold into shapes capable of binding cellular targets with high affinity and specificity. What makes CELL-SELEX AND BIOMARKER DISCOVERY such a powerful pairing is that cell-SELEX can enrich binders against native cell-surface features (often membrane proteins, glycoproteins, lipids, or complex epitopes) without needing to know the target in advance. This is especially valuable in biomarker discovery, where the “best” marker may be unknown, heterogeneous, or highly dependent on the cellular context. 1) What CELL-SELEX Is (and Why It Matters for Biomarkers) Traditional SELEX often starts with a purified target (e.g., a recombinant protein). In cell-SELEX, the “target” is a living cell population that represents a phenotype you care about—such as a disease subtype, drug-resistant cells, activated immune cells, or a specific differentiation stage. The selection process enriches aptamers that bind those cells while removing sequences that bind irrelevant or shared features. Why this matters for biomarkers: Native conformation is preserved. Cell-surface proteins keep their natural folding, post-translational modifications, and membrane context—features that can be lost in purified preparations. Unbiased discovery. You can discover binding…
“CATALOG APTAMERS & REAGENTS” usually refers to ready-to-order, pre-characterized aptamer affinity binders and the supporting assay reagents that make those binders usable in real experiments (e.g., labeling, immobilization, buffers, and controls). Aptamers themselves are short, single-stranded DNA or RNA (or related chemistries) selected from very large libraries to bind a specific target with high affinity and specificity—often described as antibody-like binding, but built from nucleic acids and produced by chemical synthesis. 1) What Are Aptamers (and Why They Matter as Reagents)? Aptamers are single-stranded nucleic acids that fold into 3D structures capable of recognizing targets such as proteins, small molecules, ions, or even cells. They are typically discovered through SELEX (Systematic Evolution of Ligands by EXponential enrichment), an iterative selection process that enriches sequences that bind the desired target. What makes aptamers especially “catalog-friendly” is that once a sequence is known, it can be reliably reproduced by chemical synthesis, and easily chemically modified (for example, adding a fluorophore or biotin) to fit common assay formats. 2) “Catalog Aptamers” vs Custom Aptamer Discovery Catalog Aptamers (ready-to-order) Catalog aptamers are fixed, known sequences that have been previously selected and are sold as standard products. Their main value…
CUSTOM APTAMER DISCOVERY & DEVELOPMENT is the process of creating target-specific single-stranded DNA or RNA aptamers—short nucleic acids that fold into 3D shapes capable of binding proteins, small molecules, cells, vesicles, or other targets with antibody-like selectivity. Most custom programs rely on SELEX (Systematic Evolution of Ligands by EXponential enrichment), then refine “hits” into robust, application-ready binders through sequencing-driven analysis and post-selection optimization. 1) What Aptamers Are (and Why They’re Used) Aptamers are typically ~15–90 nucleotides long and can be engineered to bind targets across a wide size range (from small molecules to whole cells). They’re attractive because they are chemically synthesized (batch-to-batch consistency), can be readily labeled (fluorophores, biotin, etc.), and are generally thermally stable and re-foldable—features that often simplify assay development and manufacturing. Common aptamer use cases Diagnostics & biosensors (capture probes, signal transducers, point-of-care formats) Targeted delivery & therapeutics research (cell-directed binding, payload delivery concepts) Affinity purification & analytical workflows (pull-downs, enrichment, separations) 2) The Core Workflow in Custom Aptamer Discovery A custom program is best thought of as a pipeline with four linked decisions: target format → selection strategy → analytics → optimization. Step A — Target Definition and “Bindability” Planning…
